10-Q: Journey Medical Q3 2025: Emrosi Boosts Revenue, Debt Extended

Journey Medical Corporation reports increased total revenue driven by the Emrosi launch, despite declines in legacy products, while extending its credit facility maturity and addressing going concern doubts.

Summary

• Total revenue for the three-month period ended September 30, 2025, increased by 21% to $17,631,000, up from $14,629,000 in the prior year.
• Product revenue, net, for the three-month period increased by 16% to $17,025,000, primarily due to $4,883,000 from the U.S. commercial launch of Emrosi.
• Net loss for the three-month period improved slightly to $(2,315,000) from $(2,390,000) in the prior year.
• For the nine-month period, total revenue increased by 8% to $45,779,000, with net product revenue up 6% to $45,173,000, including $9,748,000 from Emrosi.
• Net loss for the nine-month period significantly improved to $(10,184,000) from $(16,193,000) in the prior year.
• Cash and cash equivalents increased to $24,948,000 at September 30, 2025, from $20,305,000 at December 31, 2024.
• Working capital improved to $16,700,000 at September 30, 2025, from $13,000,000 at December 31, 2024.
• The company amended its Credit Facility with SWK Funding LLC, extending the maturity date to June 27, 2028, and lowering the revenue threshold for an extended interest-only period.

Sentiment

Score: 6

Explanation: The company shows positive momentum with the successful launch of Emrosi and improved liquidity, alongside a significant reduction in net loss. However, this is tempered by substantial declines in legacy product sales, increased operating expenses related to commercialization, and the explicit 'going concern' warning, indicating ongoing financial challenges and reliance on external financing.

Positives

• Total revenue for the three-month period increased by $3,002,000, or 21%, to $17,631,000.
• Emrosi's U.S. commercial launch contributed $4,883,000 in net product revenue for the three-month period and $9,748,000 for the nine-month period.
• Net loss for the three-month period decreased by $75,000, or 3%, to $(2,315,000).
• Net loss for the nine-month period decreased by $6,009,000, or 37%, to $(10,184,000).
• Net cash used in operating activities for the nine-month period decreased by $5,195,000 to $(6,157,000).
• Cash and cash equivalents increased by $4,643,000 to $24,948,000 at September 30, 2025.
• Working capital improved by $3,700,000 to $16,700,000 at September 30, 2025.
• The Credit Facility maturity date was extended from December 27, 2027, to June 27, 2028.
• The revenue threshold for extending the interest-only period under the Credit Facility was lowered from $70,000,000 to $60,000,000.
• Research and development costs decreased significantly by $9,313,000 for the nine-month period due to prior year Emrosi pre-approval expenses.
• Received $606,000 in other revenue from supplying Amzeeq to Cutia, following Cutia's marketing approval in China.

Negatives

• Accutane net product revenue decreased by $1,227,000 (31%) for the three-month period and $5,716,000 (37%) for the nine-month period due to market competition.
• Foam franchise products (Amzeeq & Zilxi) net product revenue decreased by $789,000 (38%) for the three-month period and $730,000 (16%) for the nine-month period.
• Other/legacy product revenue decreased by $249,000 (26%) for the three-month period and $678,000 (24%) for the nine-month period.
• Selling, general and administrative expenses increased by $658,000 (6%) for the three-month period and $4,361,000 (14%) for the nine-month period, primarily due to Emrosi commercialization.
• Interest expense, net, increased by $179,000 for the three-month period and $896,000 for the nine-month period due to a higher principal balance on the Credit Agreement.
• Substantial doubt exists about the company's ability to continue as a going concern for at least twelve months due to recurring and historical losses.

Risks

• Products and product candidates are subject to time and cost-intensive regulation and clinical testing, and may never be successfully developed or commercialized.
• A substantial portion of sales derive from products that may become subject to third-party generic competition, new competitor products, or increased market share of existing competitor products, which could significantly impact operating income.
• Operating in a heavily regulated industry, future legislation or administrative/executive action could adversely impact operations.
• Revenue is mainly dependent on dermatology product sales, and any setback could impair operating results.
• Competition could limit product commercial opportunity and profitability, including from generic versions.
• Risk that products do not achieve broad market acceptance, including by government and third-party payors.
• Reliance on third parties for several aspects of operations.
• Dependence on the ability to identify, develop, acquire, or in-license products and integrate them, which may be unsuccessful.
• Success of the business, including financing and revenue generation, depends on the commercialization of Emrosi and future product candidates.
• Clinical drug development is expensive, time-consuming, and uncertain, with clinical trials potentially failing to demonstrate safety and efficacy.
• Competitors could develop and commercialize similar or identical products.
• Risks related to intellectual property protection and inability to maintain sufficient patent protection.
• Business and operations could suffer from computer system failures, cyber-attacks, or cybersecurity deficiencies.
• Effects of major public health issues, epidemics, or pandemics on product revenues and clinical trials.
• Potential need to raise additional capital.
• Substantial doubt about the ability to continue as a going concern.
• Fortress Biotech, Inc. controls a voting majority of common stock, which could be detrimental to other shareholders.
• Trade policies, sanctions, and tariffs (e.g., on imports from India) could increase sourcing costs, reduce margins, or necessitate price increases.
• Unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives (e.g., Affordable Care Act, Inflation Reduction Act of 2022) could harm the business.
• Increased Congressional scrutiny of FDA approval processes and staffing cuts at the FDA could delay marketing approval or lead to more stringent requirements.
• Prolonged government shutdowns could impact FDA review of regulatory submissions and ability to access public markets for capital.

Future Outlook

The company continues to focus on the commercialization of Emrosi and regularly evaluates market conditions, its liquidity profile, and financing alternatives, including out-licensing arrangements, to enhance its capital structure. It may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives. The company will also monitor the impact of the One Big Beautiful Bill Act (OBBBA) on its income tax provision, though no material impact is expected in 2025 due to existing valuation allowances.

Management Comments

• We rely primarily on cash on hand generated from sales of our pharmaceutical products to customers to fund our core operations.
• We have relied on the proceeds from our term loan (Credit Facility) with SWK Funding LLC and our at-the-market sales program to meet additional capital and liquidity needs, specifically to fund the research and development and commercialization of Emrosi.
• We regularly evaluate market conditions, our liquidity profile, and financing alternatives, including out-licensing arrangements for our products, to enhance our capital structure.
• We may seek to raise capital through debt or equity financings to expand our product portfolio and for other strategic initiatives.

Industry Context

The dermatology pharmaceutical industry continues to see new product introductions, as evidenced by Journey Medical's Emrosi launch. However, the market also faces intense competition, as indicated by the significant sales declines of legacy products like Accutane due to market competition. The broader healthcare landscape is subject to evolving regulatory pressures, including drug pricing reforms and potential government shutdowns, which could impact commercial opportunities and profitability for companies in this sector.

Corporate Governance

Legal Proceedings

• No legal proceedings pending against the company other than routine actions, administrative proceedings, and other actions not deemed material, which are not expected to have a material adverse effect on financial condition, results of operations, or cash flows.
• The company may be subject to insured and uninsured litigation in the ordinary course of business, including tort claims for personal injury from clinical trials and property damage.

Related Party Transactions

• Shared Services Agreement with Fortress Biotech, Inc., where Journey Medical reimburses Fortress for salary, benefits, and selling, general and administrative costs for shared employees and services.
• Related party expenses to Fortress were approximately $9,000 for the three-month period and $31,000 for the nine-month period ended September 30, 2025.
• Due to related party liability was $755,000 at September 30, 2025, primarily for reimbursable expenses.
• Fortress Biotech, Inc. owns 37.4% of all classes of the company's outstanding common stock.

Stakeholder Impact

• Shareholders face potential for dilution from future equity raises (ATM program) and the inherent risks associated with the 'going concern' warning. The influence of the controlling shareholder (Fortress Biotech) is also a factor.
• Creditors, particularly SWK Funding LLC, benefit from the extended debt maturity and potentially eased repayment terms if revenue thresholds are met, but the company's 'going concern' status remains a key risk.
• Employees are affected by the company's financial stability and 'going concern' status, which could impact morale and retention, despite existing share-based compensation plans.
• Customers can expect continued availability of Emrosi and other products, but the declining sales of legacy products due to competition may indicate shifts in product focus or market presence.
• Suppliers' relationships may be influenced by the company's overall financial health and operational stability.

Next Steps

• Continue U.S. commercialization of Emrosi.
• Evaluate market conditions, liquidity profile, and financing alternatives to enhance capital structure.
• Potentially raise capital through debt or equity financings for product portfolio expansion and strategic initiatives.
• Monitor the impact of the One Big Beautiful Bill Act (OBBBA) on income tax provisions.

Key Dates

Recommendation

While the successful launch of Emrosi and improved liquidity are positive developments, the significant declines in legacy product sales and the explicit 'going concern' warning present considerable risks. The extension of the credit facility provides some breathing room, but the company's long-term profitability and ability to sustain operations without further capital raises remain uncertain. A 'hold' recommendation reflects the mixed signals, suggesting investors monitor the commercialization trajectory of Emrosi and the company's progress in achieving sustainable profitability and addressing its going concern status before making further investment decisions.

Keywords

Dermatology, Pharmaceuticals, Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss Reduction, Credit Facility, Debt Extension, Capital Raise, Going Concern, Product Commercialization, Market Competition, Regulatory Risk, Biotech